Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up ...

Eli Lilly and Company (NYSE ... driven primarily by the continued success of its GLP-1 receptor agonists, Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical ... driven primarily by the continued success of its GLP-1 receptor agonists, Mounjaro (tirzepatide) for type 2 diabetes and Zepbound ...